Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs

Table 2

Classification of TZD analogues.

---

(I) Conventional TZDs: which fit into the topology of synthetic PPARγ agonist

---

(i)With large size rings as lipophilic tail

 (a) Pyridyl TZDs

 (b) Pyrimidyl TZDs

(ii) With bulky groups as lipophilic tail

 (a) Naphthyl TZDs

 (b) Styryl TZDs

 (c) Diphenyloxy TZDs

 (d) Pyridyl-Pyrrolidinyl TZDs

(iii) With fused polynuclear/heterocyclic lipophilic tail

 (a) Indolyl TZDs

 (b) Pthalazinyl TZDs

 (c) Quinazolinyl TZDs

 (d) Quinoxalinyl TZDs

 (e) Benzpyryl (chroman) TZDs

 (f) Benzoxazolyl TZDs

 (g) Benzisoxazolyl TZDs

 (h) Benzoxazinyl TZDs

 (i) Dibenzpyryl TZDs

 (j) Imidazopyridyl TZDs

---

(II) Unconventional TZDs: which do not fit into the topology of PPARγ agonists

---

(a) TZD without characteristic lipophilic tail

(b) TZD without characteristic linkers

---